Google’s A.I. Drug Business, Isomorphic Labs, Gets Financial Boost From Thrive Capital

Isomorphic Labs, a subsidiary of Google’s parent company Alphabet, specialising in the application of artificial intelligence for drug discovery and development, has announced a successful funding round from Thrive Capital. Contending with the challenge of medical advancement, this A.I. lab is making impressive strides. The recent influx of investment from Thrive will enable the company to further enhance its A.I. models, expedite drug discovery processes, and enable a faster pipeline for potential life-saving medications. n nDespite a complex and competitive landscape, Isomorphic Labs is emerging as a significant player, attracting high-profile investors. This collaboration with Thrive Capital not only reflects the potential of A.I. in pharmaceuticals but also signifies investor confidence in Google’s venture into this sector. Read More